Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | LAP3 | P28838 | 2/20 | 0.61 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.61 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ubenimex SCHEMBL7944 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL8191715 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5819609 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL16782425 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5812930 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL9247599 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL5807154 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL16782424 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL22632072 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP | |
| Ubenimex SCHEMBL7943 | 1.00 | MME (0.66) | MMELTA4HLAP3ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571403-B2 | Methods for the treatment of non-alcoholic steatohepatitis | EIGER BIOPHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-109862888-B | Methods and pharmaceutical compositions for treating non-alcoholic steatohepatitis | 艾格尔峰生物制药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-9861601-B2 | Treatment of pulmonary arterial hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| US-20080026409-A1 | SALT-SENSITIVE HYPERTENSION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-01-31 | — | — | US | disclosed |
| US-4179573-A | (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-12-18 | — | — | US | disclosed |
| US-4052449-A | BIOLOGICALLY ACTIVE SUBSTANCE, BESTATIN, AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-10-04 | — | — | US | disclosed |
| US-4029547-A | Biologically active substance, bestatin, and production thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571403-B2 | Methods for the treatment of non-alcoholic steatohepatitis | FABP1, LIPC, CPT1A | MME 556/4885LTA4H 1290/4885LAP3 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.